BACKGROUND: Secretoneurin (SN) is a neuropeptide with potential utility as a biomarker of cardiovascular episodes. The main effect of SN is mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences calcium handling. We aimed to associate the levels of SN in plasma with different causes of heart failure. METHODS: We prospectively enrolled consecutive patients with ischaemic (ICM) and dilated (DCM) cardiomyopathy from the outpatient heart failure clinic and healthy individuals. SN was analysed from venous blood by use of the ELISA method. SN plasma levels were compared in DCM, ICM and healthy individuals with non-parametric tests. RESULTS: A total of 53 patients (81.1% male, 18.9% female; mean age 67.9 ± 12.6 years) and 34 healthy individuals (38% male, 62% female) were included in the analysis. Plasma SN levels were significantly higher in the dilated cardiomyopathy (38.8 ± 27 pmol/L) as compared with the ischaemic cardiomyopathy (19.7 ± 22.6 pmol/L) group (P = 0.006). There was no significant difference between females vs. males (27.1 ± 23 vs. 25.5 ± 26.2 pmol/L, P = NS). Plasma SN levels allowed DCM and ICM to be differentiated with 88% sensitivity and 61% specificity (P = 0.007), the cut of value is 13.3 pmol/L. Plasma SN levels differed significantly between healthy volunteers and both ICM (P < 0.0001) and DCM (P = 0.049). Plasma SN levels did not differ according to age and were not associated with comorbidities, left ventricular ejection fraction, heart failure medication, troponin, creatinine, or natriuretic peptide plasma levels. CONCLUSION: Plasma secretoneurin levels differed significantly in DCM vs. ICM, being higher in the former. Based on plasma SN levels, discrimination between DCM and ICM might be possible. Healthy individuals produce higher SN plasma levels than stable HFrEF patients.

Department of Internal Medicine and Cardiology University Hospital Ostrava Ostrava Czechia

Institute of Laboratory Medicine University Hospital Ostrava Ostrava Czechia

Institute of Laboratory Medicine University of Ostrava Ostrava Czechia

Research Center for Internal and Cardiovascular Diseases Faculty of Medicine University of Ostrava Ostrava Czechia

Social Health Institute Palacky University Olomouc Olomouc Czechia

Front Cardiovasc Med. 2024 Apr 03;11:1392484. doi: 10.3389/fcvm.2024.1392484. PubMed

Zobrazit více v PubMed

Anderson ME. Will secretoneurin be the next big thing. J Am Coll Cardiol. (2015) 65(4):352–4. 10.1016/j.jacc.2014.11.028 PubMed DOI

Plášek J, Lazárová M, Dodulík J, Šulc P, Stejskal D, Švagera Z, et al. Secretoneurin as a novel biomarker of cardiovascular episodes: are we there yet? A narrative review. J Clin Med. (2022) 11(23):7191. 10.3390/jcm11237191 PubMed DOI PMC

Ottesen AH, Louch WE, Carlson CR, Landsverk OJB, Kurola J, Johansen RF, et al. Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol. (2015) 65:339–51. 10.1016/j.jacc.2014.10.065 PubMed DOI

Luo M, Anderson ME. Mechanisms of altered Ca2+ handling in heart failure. Circ Res. (2013) 113(6):690–708. 10.1161/CIRCRESAHA.113.301651 PubMed DOI PMC

Røsjø H, Meessen J, Ottesen AH, Latini R, Omland T, GISSI HF investigators. Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-heart failure trial. Clin Biochem. (2023) 118:110595. 10.1016/j.clinbiochem.2023.110595 PubMed DOI

Aakre KM, Ottesen AH, Strand H, Faaren AL, Alaour B, Torsvik J, et al. Biologial variation of secretoneurin; a novel cardiovascular biomarker implicated in arrhythmogenesis. Clin Biochem. (2021) 98:74–7. 10.1016/j.clinbiochem.2021.09.014 PubMed DOI

Dodulík J, Václavík J, Lazarová M, Šulc P, Evin L, Stejskal D, et al. Secretoneurin plasma levels in patients with different etiologies of heart failure: preliminary data—abstracts of the heart failure 2023 and the world congress on acute heart failure, 20–23 May 2023, Prague, Czechia. Eur J Heart Fail. (2023) 25(S2):144. 10.1002/ejhf.2927 DOI

Ottesen AH, Carlson CR, Eken OS, Sadredini M, Myhre PL, Shen X, et al. Secretoneurin is an endogenous CaMKII inhibitor that attenuates Ca2+-dependent arrhythmia. Circ Arrhythm Electrophysiol. (2019) 12:007045. 10.1161/CIRCEP.118.007045 PubMed DOI

Brynildsen J, Petäjä L, Myhre PL, Lyngbakken MN, Nygård S, Stridsberg M, et al. Circulating secretoneurin concentrations after cardiac surgery: data from the FINNish acute kidney injury heart study. Crit Care med. (2019) 47(5):e412–9. 10.1097/CCM.0000000000003670 PubMed DOI

Brynildsen J, Myhre PL, Lynbakken MN, Klaeboe LG, Sridsberg M, Christensen G, et al. Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis. Clin Biochem. (2019) 71:17–23. 10.1016/j.clinbiochem.2019.06.008 PubMed DOI

Røsjø H, Stridsberg M, Ottesen AH, Nygård S, Christensen G, Pettilä V, et al. Prognostic value of secretoneurin in critically ill patients with infections. Crit Care. (2016) 44(10):1882–90. 10.1097/CCM.0000000000001832 PubMed DOI

Rosjo H, Meessen J, Ottesen AH, Omland H, GISSI-HF study. Circulating secretoneurin concentrations provide independent prognostic information to established risk indices in patients with chronic heart failure. Eur Heart J. (2022) 43(2):ehac544.912. 10.1093/eurheartj/ehac544.912 DOI

Miller WL, Jaffe AS. Biomarkers in heart failure: the importance of inconvenient details. ESC Heart Fail. (2016) 3(1):3–10. 10.1002/ehf2.12071 PubMed DOI PMC

Zhao Y, Godier-Furnemont A, Bax NAM, Bouten CVC, Brown LM, Vunjak-Novakonic G. Changes in extracellular matrix in failing human non-ischemic nad ischemic hearts with mechanical unloading. J Mol Cell Cardiol. (2022) 166:137–51. 10.1016/j.yjmcc.2022.02.003 PubMed DOI PMC

Kosuge M, Ebina T, Ishikawa T, Hibi K, Tsukara K, Okuda J, et al. Serum amyloid A is a better predictor of clinical outcomes than C-reative protein in non-ST-segment elevation acute coronary syndromes. Circ J. (2007) 71(2):186–90. 10.1253/circj.71.186 PubMed DOI

Lepper PM, Kleber ME, Grammer TB, Hoffmann K, Dietz S, Winkelmann BR, et al. Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease—results from the ludwigshafen risk and cardiovascular health study (LURIC). Atherosclerosis. (2011) 219(1):291–7. 10.1016/j.atherosclerosis.2011.06.001 PubMed DOI

Frangogiannis NG. The extracellular matrix in ischemic and nonischemic heart failure. Circ Res. (2019) 125(1):117–46. 10.1161/CIRCRESAHA.119.311148 PubMed DOI PMC

Sen L, Cui G, Fonarow GS, Laks H. Differences in mechanisms of SR dysfunction in ischemic vs. idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. (2000) 279(2):H709–18. 10.1152/ajpheart.2000.279.2.H709 PubMed DOI

Baqi DH, Ahmed SF, Baba HO, Fattah FH, Salih AM, Ali RM, et al. Hypocalcemia as a cause of reversible heart failure: a case report and review of the literature. Ann Med Surg. (2022) 77:103572. 10.1016/j.amsu.2022.103572 PubMed DOI PMC

Schmitz T, Thilo Ch, Linseisen J, Heier M, Peters A, Kuch B, et al. Low serum calcium is associated with higher long-term mortality in myocardial infarction patients from a population-based registry. Sci Rep. (2021) 11(1):2476. 10.1038/s41598-021-81929-7 PubMed DOI PMC

Barbagallo M, Dominguez LJ, Licata G, Resnick LM. Effects of aging on serum ionized and cytosolic free calcium: relation to hypertension and diabetes. Hypertension. (1999) 34(2):902–6. 10.1161/01.HYP.34.4.902 PubMed DOI